Impact

NeuroShield has the potential to impact millions of patients affected by viral infections with neurological risk. In large-scale outbreaks, studies have shown that up to 30 to 50 percent of patients may experience neurological symptoms, highlighting the scale and urgency of the problem.

 

By enabling earlier detection and targeted intervention, NeuroShield aims to reduce the likelihood of viruses reaching the brain and causing long-term damage. This could lead to improved recovery outcomes, fewer neurological complications, and a reduced burden on healthcare systems worldwide.

 

By focusing on early-stage neuroprotection, NeuroShield introduces a new approach to managing viral infections at a global scale. As similar threats continue to emerge, systems that identify and respond to neurological risk earlier have the potential to reshape how the world detects, treats, and prevents virus-related brain damage.